Zhu Xiaofan, Ng Hoi Ioi, Xuan Liming, Long Yan, Mao Yan, Shi Yu, Sun Liying, Liang Bo, Scaglia Fernando, Zhu Zhijun, Choy Kwong Wai
Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong, China.
Liver Transplantation Center, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
Data Brief. 2020 Jan 25;29:105183. doi: 10.1016/j.dib.2020.105183. eCollection 2020 Apr.
Graft derived cell-free DNA was recently reported as a non-invasive biomarker to detect graft damage or rejection after liver transplantation. There are a number of methods for quantification of Gcf-DNA, including quantitative-PCR, digital droplet PCR and massively parallel sequencing (next generation sequencing). Here we present the NGS data and fragment size distribution of cell-free DNA in the plasma of patients with inborn errors of metabolism who underwent living-related liver transplantation. For more insights please see Analysis of fragment size distribution of cell-free DNA: a potential noninvasive marker to monitor graft damage in living-related liver transplantation for inborn errors of metabolism. [1].
移植来源的游离DNA最近被报道为一种非侵入性生物标志物，用于检测肝移植后移植器官的损伤或排斥反应。有多种定量Gcf-DNA的方法，包括定量聚合酶链反应、数字液滴聚合酶链反应和大规模平行测序（下一代测序）。在此，我们展示了接受活体亲属肝移植的代谢性遗传病患者血浆中游离DNA的二代测序数据和片段大小分布。欲了解更多详情，请参阅《游离DNA片段大小分布分析：一种监测活体亲属肝移植治疗代谢性遗传病中移植器官损伤的潜在非侵入性标志物》[1]。
